These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

471 related items for PubMed ID: 19187170

  • 21. Safety and effectiveness of biphasic insulin aspart 30/70 (NovoMix 30) when switching from human premix insulin in patients with type 2 diabetes: subgroup analysis from the 6-month IMPROVE observational study.
    Shah S, Benroubi M, Borzi V, Gumprecht J, Kawamori R, Shaban J, Shestakova M, Wenying Y, Valensi P, IMPROVE Study Group Expert Panel.
    Int J Clin Pract; 2009 Apr; 63(4):574-82. PubMed ID: 19210701
    [Abstract] [Full Text] [Related]

  • 22. The A1chieve study: a 60 000-person, global, prospective, observational study of basal, meal-time, and biphasic insulin analogs in daily clinical practice.
    Shah SN, Litwak L, Haddad J, Chakkarwar PN, Hajjaji I.
    Diabetes Res Clin Pract; 2010 May; 88 Suppl 1():S11-6. PubMed ID: 20466163
    [Abstract] [Full Text] [Related]

  • 23. Glycaemic control and hypoglycaemia in the PRESENT study.
    Almustafa M, Yeo JP, Khutsoane D.
    Diabetes Res Clin Pract; 2008 Sep; 81 Suppl 1():S10-5. PubMed ID: 18687501
    [Abstract] [Full Text] [Related]

  • 24. The effects of insulin glargine treatment and an educational programme on glycaemic control in type 2 diabetes patients in clinical practice.
    Schreiber SA, Russmann A.
    Curr Med Res Opin; 2006 Feb; 22(2):335-41. PubMed ID: 16466605
    [Abstract] [Full Text] [Related]

  • 25. Overnight CSII as supplement to oral antidiabetic drugs in type 2 diabetes.
    Parkner T, Møller MK, Chen JW, Laursen T, Jørgensen C, Smedegaard JS, Lauritzen T, Christiansen JS.
    Diabetes Obes Metab; 2008 Jul; 10(7):556-63. PubMed ID: 17593233
    [Abstract] [Full Text] [Related]

  • 26. Therapy conversion to biphasic insulin aspart 30 improves long-term outcomes and reduces the costs of type 2 diabetes in Saudi Arabia.
    Ali M, White J, Lee CH, Palmer JL, Smith-Palmer J, Fakhoury W, Valentine WJ.
    J Med Econ; 2008 Jul; 11(4):651-70. PubMed ID: 19450074
    [Abstract] [Full Text] [Related]

  • 27. Evaluation of glargine group-start sessions in patients with type 2 diabetes as a strategy to deliver the service.
    Tahrani AA, Digwood S, Lee C, Moulik P.
    Int J Clin Pract; 2007 Feb; 61(2):329-35. PubMed ID: 17263721
    [Abstract] [Full Text] [Related]

  • 28. Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China.
    Palmer JL, Gibbs M, Scheijbeler HW, Kotchie RW, Nielsen S, White J, Valentine WJ.
    Adv Ther; 2008 Aug; 25(8):752-74. PubMed ID: 18704282
    [Abstract] [Full Text] [Related]

  • 29. Biphasic insulin aspart in the treatment of type 2 diabetes mellitus.
    Cucinotta D, Russo GT.
    Expert Opin Pharmacother; 2009 Dec; 10(17):2905-11. PubMed ID: 19929709
    [Abstract] [Full Text] [Related]

  • 30. Safety and efficacy of biphasic insulin aspart 30 in type 2 diabetes patients switched from either biphasic or basal human insulin: results from the Gulf cohort of the A1 chieve study.
    Almansari A, Khader S, Kharawagh A, AbdelFattah W, Badawy T.
    Int J Clin Pract; 2014 Jul; 68(7):850-6. PubMed ID: 24548757
    [Abstract] [Full Text] [Related]

  • 31. Premixed insulin treatment for type 2 diabetes: analogue or human?
    Garber AJ, Ligthelm R, Christiansen JS, Liebl A.
    Diabetes Obes Metab; 2007 Sep; 9(5):630-9. PubMed ID: 17697056
    [Abstract] [Full Text] [Related]

  • 32. Postprandial versus preprandial dosing of biphasic insulin aspart in elderly type 2 diabetes patients.
    Warren ML, Conway MJ, Klaff LJ, Rosenstock J, Allen E.
    Diabetes Res Clin Pract; 2004 Oct; 66(1):23-9. PubMed ID: 15364158
    [Abstract] [Full Text] [Related]

  • 33. Type 2 diabetes mellitus--guidelines for initiating insulin therapy.
    Yeap BB.
    Aust Fam Physician; 2007 Jul; 36(7):549-53. PubMed ID: 17619673
    [Abstract] [Full Text] [Related]

  • 34. The effectiveness and safety of beginning insulin aspart together with basal insulin in people with type 2 diabetes in non-Western nations: results from the A₁chieve observational study.
    Home PD, Latif ZA, González-Gálvez G, Prusty V, Hussein Z.
    Diabetes Res Clin Pract; 2013 Sep; 101(3):326-32. PubMed ID: 24119590
    [Abstract] [Full Text] [Related]

  • 35. [Initiating insulin therapy in patients with diabetes mellitus type 2: in a transmural setting is at least as effective as in an outpatient setting; a retrospective study with a 4-year follow-up].
    Rosendal H, Vondeling H, de Witte LP, Hutubessy RC, van Beekum WT, Heine RJ.
    Ned Tijdschr Geneeskd; 2002 Jan 26; 146(4):166-71. PubMed ID: 11845567
    [Abstract] [Full Text] [Related]

  • 36. Efficacy, safety and acceptability of biphasic insulin aspart 30 in Indian patients with type 2 diabetes: results from the PRESENT study.
    Sharma SK, Joshi SR, Kumar A, Unnikrishnan AG, Hoskote SS, Moharana AK, Chakkarwar PN, Vaz JA, PRESENT Study Group.
    J Assoc Physicians India; 2008 Nov 26; 56():859-63. PubMed ID: 19263683
    [Abstract] [Full Text] [Related]

  • 37. Initiating therapy or switching to biphasic insulin aspart improves glycaemic control in type 2 diabetes: an Indian experience from the A1chieve study.
    Kumar A, Sharma SK, Rajput R, Unnikrishnan AG.
    J Assoc Physicians India; 2013 Jan 26; 61(1 Suppl):16-20. PubMed ID: 24482982
    [Abstract] [Full Text] [Related]

  • 38. Comparison of glycaemic control in patients with Type 2 diabetes on basal insulin and fixed combination oral antidiabetic treatment: results of a pilot study.
    De Mattia G, Laurenti O, Moretti A.
    Acta Diabetol; 2009 Mar 26; 46(1):67-73. PubMed ID: 19030772
    [Abstract] [Full Text] [Related]

  • 39. Health outcomes and economic impact of therapy conversion to a biphasic insulin analog pen among privately insured patients with type 2 diabetes mellitus.
    Cobden D, Lee WC, Balu S, Joshi AV, Pashos CL.
    Pharmacotherapy; 2007 Jul 26; 27(7):948-62. PubMed ID: 17594200
    [Abstract] [Full Text] [Related]

  • 40. The safety and efficacy of biphasic insulin aspart 30 (BIAsp 30) in Iranians with type 2 diabetes: an open-label, non-randomised, multi-centre observational study--the Iran subgroup of the IMPROVE™ study.
    Esteghamati A, Rajabian R, Amini M, Bahrami A, Khamseh ME, Afkhami-Ardekani M, Rizi EP.
    Endokrynol Pol; 2010 Jul 26; 61(4):364-70. PubMed ID: 20806180
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.